贝达喹啉-普托马尼方案治疗耐药结核的不良事件系统综述
该系统综述整合临床试验、实施研究和药物警戒研究的安全性数据,分析含贝达喹啉-普托马尼的耐药结核短程方案相关不良事件(AE)。共纳入14项研究,临床试验AE报告率(62.2-100%)高于实施研究(41.8-72.8%),严重AE发生率为2.2-30.2%。需在真实世界中加强主动监测。
要点
- 临床试验AE报告率高于实施研究,提示检测方法影响AE识别。
- 严重AE发生率为2.2-30.2%,部分需中断或停用抗结核药物。
- AE总体完全恢复率79.2%,但23-32%患者治疗结束后仍有AE。
核心结论
- 含贝达喹啉-普托马尼方案的不良事件谱因研究设计而异,临床试验报告率更高。
- 严重AE可导致药物中断或停用,需早期识别和管理以提高耐受性。
研究设计与样本
- 系统综述,检索PubMed、Medline和Web of Science,纳入14项研究(7项临床试验、6项实施研究、1项药物警戒研究)。
主要发现
- 临床试验AE报告率为62.2-100%,实施研究为41.8-72.8%。
- 严重AE发生率为2.2-30.2%。
- 严重AE患者中7.7-54.3%需中断结核药物,3.5-13%需停用结核药物。
- AE结局完全恢复者占79.2%,但23-32%患者治疗完成后仍报告AE。
临床怎么用
- 临床应早期识别和管理AE,以提高方案耐受性、减少并发症并优化结局。
- 真实世界应用中需考虑主动监测AE,而非仅依赖自发报告。
局限性
- 临床试验与实施研究的AE检测方法不同,影响报告率可比性。
- 实施研究和药物警戒研究依赖自发报告,可能低估AE发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug-resistant tuberculosis (TB) containing a bedaquiline-pretomanid-based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by combining safety data from clinical trials, implementation and pharmacovigilance studies. We conducted a search using PubMed, Medline and Web of Science to identify studies that reported AE data for bedaquiline-pretomanid-based regimens. In total, 14 studies from various countries were included in the analysis, comprising seven clinical trials, six implementation studies and one pharmacovigilance study. AE detection methods differed between clinical trials and implementation studies. Clinical trials utilised structured and standardised detection methods, whereas implementation and pharmacovigilance studies relied on spontaneous reporting with a higher prevalence of AEs reported in clinical trials (62.2-100%) compared to implementation studies (41.8-72.8%). Serious AEs developed in 2.2-30.2% of patients. Among those with serious AEs, 7.7-54.3% required interruption of TB drugs, while 3.5-13% required withdrawal of TB drugs. AE outcomes showed full recovery in 79.2%. However, 23-32% of patients reported AEs even after completing their treatment. Understanding AEs is crucial for healthcare professionals to enhance patient care, as early detection and appropriate management of AEs is essential in TB treatment to increase tolerability, minimise complications and optimise clinical outcomes. Further research is necessary to implement active monitoring for this new TB regimen in real-world settings.
引用
- Maria N, Larasati AL, Hamdani IY, et al. Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies. Br J Clin Pharmacol. 2026. PMID: 42121320. doi:10.1002/bcp.70541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。